Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06562153 · ClinicalTrials.gov registry record
fMRI Accelerated TMS Depression
A clinical trial of Depression, sponsored by Medical University of South Carolina.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT06562153: Recruiting study of Depression, sponsored by Medical University of South Carolina.
NCT06562153 is a study of Depression that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 20 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06562153, a study of Depression, is actively recruiting participants, sponsored by Medical University of South Carolina.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to investigate whether phenotypic-related brain states revealed by a novel INSCAPE ("Individualized Network-based Single-frame Coactivation Pattern Estimation") neuroimaging method in Major Depressive Disorder (MDD) patients can track brain recovery of MDD patients over an accelerated antidepressant transcranial magnetic stimulation (TMS) treatment.
Primary Outcome
Two magnetic resonance imaging (MRI) scans will be collected at baseline and after the course of 5-day TMS treatment. A neuroimaging analysis method called "INSCAPE" will be used to get the dynamic brain state from the MRI data. The changes in brain states between baseline and after treatment MRI data will be calculated as the outcome measure.
Conditions Studied
Interventions
- OTHER Neuroimaging with Magnetic Resonance Imaging (MRI)
Study Locations (1)
South Carolina
- 30 Bee Street - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-23 |
| Est. Completion | 2026-08-05 |
What NCT06562153 shows while recruiting
NCT06562153 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Neuroimaging with Magnetic Resonance Imaging (MRI) is the first listed.
NCT06562153 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT06562153 about?
NCT06562153 is a clinical study titled "fMRI Accelerated TMS Depression". This study aims to investigate whether phenotypic-related brain states revealed by a novel INSCAPE ("Individualized Network-based Single-frame Coactivation Pattern Estimation") neuroimaging method in Major Depressive Disorder (MDD) patients can track brain recovery of MDD patients over an accelerate...
What is the current status of trial NCT06562153?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2024-09-23. Estimated completion is 2026-08-05.
What conditions does trial NCT06562153 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT06562153?
The interventions under investigation include: Neuroimaging with Magnetic Resonance Imaging (MRI) (OTHER).
Who is sponsoring clinical trial NCT06562153?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06562153 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06562153's enrollment target sits among peer trials
20 612th of 679 higher than 58 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
Depression and Driving
RECRUITING
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy